Dr Reddys Laboratories (RDY) Net Income towards Common Stockholders Growth (3y) (2012 - 2026)
Powered by 
Analysis
Dr Reddys Laboratories (RDY) Net Income towards Common Stockholders Growth (3y) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.60 Bn | 38.94 Bn | 2.15 Bn | 14.04% |
| 2 | Viatris | 19.15 Bn | 18.27 Bn | 1.46 Bn | -34.81% |
| 3 | Dr Reddys Laboratories | 9.86 Bn | 9.69 Bn | 396.53 Mn | -34.93% |
| 4 | Amneal Pharmaceuticals | 5.49 Bn | 5.36 Bn | 334.51 Mn | 80.10% |
| 5 | Bausch Health Companies | 2.35 Bn | 516.55 Mn | 2.10 Bn | 112.75% |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | - |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 61.73% |
| 8 | Amphastar Pharmaceuticals | 996.17 Mn | 706.05 Mn | 93.47 Mn | 4.72% |
| 9 | Fennec Pharmaceuticals | 404.39 Mn | 363.15 Mn | 17.15 Mn | 33.27% |
| 10 | RedHill Biopharma | 176.59 Mn | 176.59 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -34.93% |
| Mar 31, 2026 | -71.29% |
| Dec 31, 2025 | -55.15% |
| Sep 30, 2025 | 2.73% |
| Jun 30, 2025 | 2.46% |
| Mar 31, 2025 | -97.23% |
| Dec 31, 2024 | 51.64% |
| Sep 30, 2024 | 17.24% |
| Jun 30, 2024 | 7.59% |
| Mar 31, 2024 | 26.91% |
| Dec 31, 2023 | 30.22% |
| Sep 30, 2023 | 290.79% |
| Jun 30, 2023 | 17.80% |
| Mar 31, 2023 | 28.85% |
| Dec 31, 2022 | 15.98% |
| Sep 30, 2022 | 58.74% |
| Jun 30, 2022 | 0.22% |
| Mar 31, 2022 | -42.61% |
| Dec 31, 2021 | -8.67% |
| Sep 30, 2021 | 9.93% |